Risk factors for non-alcoholic fatty liver disease in symptomatic gallbladder disease patients.

Factores de riesgo para hígado graso no-alcohólico en pacientes con colelitiasis sintomática.

Published 2016-06-30


https://doi.org/10.30554/archmed.16.1.1563.2016
Open | Download
PDF (Spanish) FLIP HTML (Spanish)
Issue
Vol. 16 No. 1
Section
Research Articles
How to Cite
Díaz-Rosales, J. de D., Enríquez-Domínguez, L., & Díaz-Torres, B. (2016). Risk factors for non-alcoholic fatty liver disease in symptomatic gallbladder disease patients. Archivos De Medicina (Manizales), 16(1), 98-108. https://doi.org/10.30554/archmed.16.1.1563.2016
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX
DOI

https://doi.org/10.30554/archmed.16.1.1563.2016
Dimensions
PlumX

How to Cite

Díaz-Rosales, J. de D., Enríquez-Domínguez, L., & Díaz-Torres, B. (2016). Risk factors for non-alcoholic fatty liver disease in symptomatic gallbladder disease patients. Archivos De Medicina (Manizales), 16(1), 98-108. https://doi.org/10.30554/archmed.16.1.1563.2016

Download Citation

Juan de Dios Díaz-Rosales
Lenin Enríquez-Domínguez
Beatriz Díaz-Torres
Show authors biography

Juan de Dios Díaz-Rosales,

General Surgeon. Master of Science of Health 

Surgery Service/Hospital General de Zona No. 35 IMSS

Health Sciences Department/Universidad Autónoma de Ciudad Juárez

Lenin Enríquez-Domínguez,

General Surgeon.

Surgery Service/Hospital General Regional No. 66 IMSS

 

Beatriz Díaz-Torres,

Health Department Chief

Health Sciences Department/Universidad Autónoma de Ciudad Juárez

Most read articles by the same author(s)

Objective: identify the prevalence and risk factors associated to non-alcoholic fatty liver disease in patients with symptomatic cholelithiasis. Material and methods: Patients
with symptomatic cholelithiasis with surgical treatment (laparoscopic cholecystectomy) and hepatic biopsy. Inclusion criteria were: diagnosis of symptomatic cholelithiasis,
age from 18 to 65 years old, diagnostic hepatic biopsy, and informed consent signed. Variables were: age, sex, weight, height, body mass index, waist circumference, hip circumference, waist-hip index, blood pressure, fasting glucose, lipid panel and metabolic syndrome. Patients were divided into two groups: group I with non-alcoholic fatty liver disease and group II with normal liver. Results: 248 patients were included, 85,5%
were females and 14,5% were males. The prevalence of non-alcoholic fatty liver disease was 77,5%. There were statistical differences between groups in variables: weight (p=<0,0001), waist circumference (p=<0,0001), hip circumference (p=<0,0001), blood pressure (p=<0,0001), HDL levels (p=<0,0001), and presence of metabolic syndrome
(p=<0,0001). Conclusion: overweight and obesity determined by body mass index, HDL levels, and metabolic syndrome are independent risk factors that increase the
prevalence of non-alcoholic fatty liver disease in patients with symptomatic cholelithiasis.

Article visits | PDF visits

Downloads

Download data is not yet available.
  1. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009;8 Suppl 1:S4-S8.
  2. Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab. 2008;34(6 Pt 2):634-637.
  3. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413-1419.
  4. Ruffillo G, Fassio E, Alvarez E, et al. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol. 2011;54(1):160-163.
  5. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387-1395.
  6. Lizardi-Cervera J, Laparra DIB, Chávez-Tapia NC, Ostos MER, Esquivel MU. [Prevalence of NAFLD and metabolic syndrome in asymtomatics subjects]. Rev Gastroenterol México. 2006;71(4):453-459.
  7. Salas-Flores R, González-Pérez B, Echegollen-Guzmán A. Hepatic steatosis and type 2 diabetes mellitus in health workers. Rev Med Inst Mex Seguro Soc. 2012;50(1):13-18.
  8. Almobarak AO, Barakat S, Khalifa MH, Elhoweris MH, Elhassan TM, Ahmed MH. Non alcoholic fatty liver disease (NAFLD) in a Sudanese population: What is the prevalence and risk factors? Arab J Gastroenterol. February 2014.
  9. Caballería L, Arteaga I, Pera G, et al. [Risk factors associated with non-alcoholic fatty liver disease: a case-control study]. Med Clin (Barc). 2013;141(6):233-239.
  10. Duncan CB, Riall TS. Evidence-based current surgical practice: calculous gallbladder disease. J Gastrointest Surg. 2012;16(11):2011-2025.
  11. Méndez-Sánchez N, Jessurun J, Ponciano-Rodríguez G, Alonso-de-Ruiz P, Uribe M, Hernández-Avila M. Prevalence of gallstone disease in Mexico. A necropsy study. Dig Dis Sci. 1993;38(4):680-683.
  12. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
  13. Rosales Ricardo Y. [Anthropometry in the diagnosis of obese patients: a review]. Nutr Hosp. 2012;27(6):1803-1809.
  14. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35 Suppl 1(Supplement_1):S64-S71.
  15. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163(5):525-541.
  16. Fracanzani AL, Valenti L, Russello M, et al. Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease. PLoS One. 2012;7(7):e41183.
  17. Ramos-De la Medina A, Remes-Troche JM, Roesch-Dietlen FB, Pérez-Morales AG, Martinez S, Cid-Juarez S. Routine liver biopsy to screen for nonalcoholic fatty liver disease (NAFLD) during cholecystectomy for gallstone disease: is it justified? J Gastrointest Surg. 2008;12(12):2097-2102; discussion 2102.
  18. Koller T, Kollerova J, Hlavaty T, Huorka M, Payer J. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand J Gastroenterol. 2012;47(2):197-203.
  19. Loria P, Lonardo A, Lombardini S, et al. Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. J Gastroenterol Hepatol. 2005;20(8):1176-1184.
  20. Roesch-Dietlen F, Pérez-Morales A, Melo-Santisteban G, et al. [Frequency and clinical, biochemical and histological characteristics of nonalcoholic fatty liver disease in patients with gallstone disease]. Cir Cir. 2008;76(1):37-42.
  21. Yener O, Aksoy F, Demır M, Özçelık A, Erengül C. Gallstones associated with nonalcoholic steatohepatitis (NASH) and metabolic syndrome. Turk J Gastroenterol. 2010;21(4):411-415.
  22. Ju DY, Choe YG, Cho YK, et al. The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults. Clin Mol Hepatol. 2013;19(2):140-147.
  23. Flores-Huerta S. Obesidad abdominal y síndrome metabólico. Bol Med Hosp Infant Mex. 2008;65(2):83-85.
  24. Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol. 2012;56(5):1145-1151.
  25. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865-873.

Information

Google Scholar Profile

Author Guidelines